

Special Issue

Extracellular Vesicles as a Platform for Cancer Treatment

Message from the Guest Editor

Extracellular vesicles (EVs), small membrane-based nanovesicles naturally released from various cells, have tissue tropism and facilitate long distance intercellular communication by carrying and delivering biological materials. EVs from certain cells revealed natural anti-tumor activity with specific tumor targetability. Since drugs can be loaded in to EVs, they are also considered as promising drug carriers. Antitumor activity of EVs can be enhanced by meticulous bioengineering techniques, such as loading chemotherapeutic drugs and incorporating tumor-targeting moieties. EV mimetics (EVMs), artificially generated from various cells, are functionally similar to EVs and thus can be a substitute EVs for cancer therapy. Accumulating evidence shows that bio-nanovesicles (EVs and EVMs) can be effective biological armors, since they have huge potential to fight intractable cancers and they might be useful in cancer therapeutics. This Special Issue will focus on therapeutic applications of EVs and EVMs for cancerous diseases and on strategies of reinforcing the therapeutic efficacy of bio-nanovesicles. , MD, PhD

Guest Editor

Prof. Dr. Byeong-Cheol Ahn

Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea

Deadline for manuscript submissions

closed (28 February 2021)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/53633

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).